Blog Tag: AngioJet® Thrombectomy System
According to a Boston Scientific Corp. press release from May 15, 2014, the company has entered into a definitive agreement to acquire the Interventional Division of Bayer AG for $415 million. The transaction is expected to close in the second half of 2014. The press release notes that “[i]n 2013, Bayer Interventional generated sales of approximately $120 million.”
Included in the transaction are Bayer Interventional technologies designed to treat coronary and peripheral vascular disease. These technologies include “the AngioJet® Thrombectomy System and the Fetch® 2 Aspiration Catheter, which use endovascular techniques to remove blood clots from blocked arteries and veins, and the JetStream® Atherectomy System, a minimally invasive device used to remove plaque from diseased peripheral arteries.”
According to the press release, “[t]he acquisition is expected to improve Boston Scientific’s access to a number of attractive segments in the peripheral space, including the growing atherectomy and thrombectomy categories.”
Jeff Mirviss, president, Peripheral Interventions, Boston Scientific describes the effects of the transaction saying:
The addition of Bayer Interventional will expand our commercial footprint and enhance our ability to provide physicians and healthcare systems with a complete portfolio of solutions to treat challenging vascular conditions, . . . We believe this acquisition will accelerate the growth of our Peripheral Interventions business and strengthen our position as a global leader in peripheral therapies.